Drug intelligence / Profile preview

CALCOW D3

Development stage: Unknown
Lead developer: Wellmed Pharma
Modality: Small Molecules
Administration: Oral

Overview

CALCOW D3 is a nutritional supplement syrup developed and marketed by Wellmed Pharma. It is formulated to address calcium and vitamin D3 deficiencies and to support bone health. Each 5 ml serving contains a combination of calcium salts, including calcium citrate (250 mg), calcium aspartate (250 mg), and calcium orotate (100 mg), along with 400 IU of vitamin D3 (cholecalciferol). Calcium is a critical mineral for bone density and skeletal integrity, while vitamin D3 acts as a regulator of calcium and phosphate homeostasis by promoting intestinal calcium absorption. The product is part of Wellmed Pharma's marketed portfolio in India.

Brand names: CALCOW D3

Targets

CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on CALCOW D3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CALCOW D3.

Explore the full profile